Law firm Kaplan Fox & Kilsheimer LLP has announced an investigation into Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for possible securities law violations on behalf of shareholders. The investigation follows Fulcrum's June 1, 2026 announcement that it was discontinuing its pociredir program for sickle cell disease after the U.S. Food and Drug Administration raised serious concerns about the drug's benefit-risk profile. Fulcrum Therapeutics stock fell 51.09% the following trading session, dropping from $6.42 to $3.14 per share, a decline of $3.28 per share. Investors who suffered losses may be watching this investigation closely.
Key Points
- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is the subject of a shareholder investigation by Kaplan Fox & Kilsheimer LLP
- Kaplan Fox is probing potential securities violations connected to the discontinuation of the pociredir sickle cell disease program
- FULC shares dropped 51.09% on June 2, 2026, falling from $6.42 to $3.14 per share following the program's cancellation
- Investors who held FULC shares and suffered losses may be eligible to participate in the investigation
Pociredir Discontinuation and FDA Benefit-Risk Concerns
Fulcrum Therapeutics announced after market close on June 1, 2026, that it was discontinuing its pociredir program for sickle cell disease. The company stated that meeting minutes from end-of-phase interactions with the FDA reflected heightened concerns about pociredir's benefit-risk profile. These concerns stemmed from an unexpectedly high rate of secondary hematologic malignancies observed with Tazverik® (tazemetostat), another PRC2 inhibitor, which was withdrawn from the global market in March 2026. The FDA subsequently concluded that any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk, leaving the company with no viable regulatory path forward for pociredir.
Sharp Share Price Decline Following Program Cancellation
The market reaction to Fulcrum Therapeutics' disclosure was severe. Shares closed at $6.42 on June 1, 2026, before the announcement, and fell to $3.14 per share at the close of trading on June 2, 2026. That represents a single-session decline of $3.28 per share, or 51.09%, according to the release. The steep drop reflects investor concern about the clinical-stage biopharmaceutical company's pipeline following the removal of what the release suggests was a key development program. The immediate share price impact beyond that session was not clear from available public information.
Kaplan Fox Securities Investigation Into FULC Shareholders' Claims
Kaplan Fox & Kilsheimer LLP, a nationally recognised plaintiffs' securities litigation firm founded in 1956, has opened an investigation into whether Fulcrum Therapeutics violated securities laws in connection with these events. The firm states it has recovered more than $10 billion for clients across its history. Shareholders who suffered losses in FULC and who may have information relevant to the investigation are encouraged by the firm to come forward. The announcement notes that contacting the firm does not create an attorney-client relationship.




Please wait processing your request...